Skip to main content

Table 4 Literature review of SBRT for cholangiocarcinoma

From: Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma

Reference Year Patients (n) Total Dose (Gy) Fractions 12-month LC (%) Median OS (months) Comments
Herfarth et al. [13] 2001 3 14 - 26 1 71 NR Target volume covered by 80% isodose
Tse et al. [16] 2008 10 32.5 6 65 15 Hypofractionated stereotactic radiotherapy
Goodman et al. [12] 2010 5 18 - 30 1 77 29 Single-fraction dose escalation study
Kopek et al. [14] 2010 27 45 3 NR 11 22% rate of serious GI injury
Polistina et al. [15] 2011 10 30 3 NR 36 All patients received concurrent gemcitabine
Current Study 2012 10 55 5 100 14 Includes both recurrent and metastatic lesions
  1. Abbreviations: LC Local control, OS Overall survival, NR Not reported, GI Gastrointestinal.